The Survey Research Facility (SRF) was founded in April 1991 and has been a Cancer Center Shared Resource since 2003. Its purpose is to facilitate the conduct of high quality science through the provision of excellent consultation and service delivery for all aspects of survey design and conduct for Mayo Clinic Cancer Center (MCCC) investigators. The SRF strives for excellence by providing high quality and efficient service delivery by deploying "state of the science" methods in the areas of instrument development, sampling, mailing, telephoning, response tracking, instrument processing, and data file preparation. The SRF is the only Mayo Clinic facility offering this comprehensive set of services. The SRF has conducted over 1,500 survey-based studies since its inception. During the current grant period alone (2004-07), the SRF conducted 658 separate survey studies. Overall, approximately 16% of the studies conducted by the SRF are cancer-related, with the vast majority (approximately 90%) of those done in collaboration with MCCC members. For MCCC investigators, this resource has and will continue to provide expert consultation and support for the conduct of survey research relevant to their research endeavors. To date, these have been aimed at risk factor assessment, obtaining outcomes following diagnosis or treatment, recruitment for clinical trials, assessing attitudes and behaviors related to cancer screening, assessing the acceptability of cancer screening methods, determination of family trees for genetic studies, assessing satisfaction with cancer related treatment and associated health care encounters, assessing informational needs for cancer patients, assessment of the willingness to help others to stop smoking (cancer prevention), psychological scale development pertinent to intervening on adolescents who use tobacco, and quality of life assessment in cancer patients. The demand for SRF services by MCCC investigators continues to remain high. The SRF is working to expand its range of services, especially with respect to qualitative analysis and psychometric expertise related to patient-reported outcomes and quality of life assessment. The SRF will also expand the capabilities of its project and respondent tracking systems and implement processes and procedures to assure compliance with the new HIPAA regulations as they pertain to survey work.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43

Showing the most recent 10 out of 340 publications